Sujal Shah Biography and Net Worth

Mr. Shah has served as our President and Chief Executive Officer since March 2017. Previously, he served as our Chief Financial Officer since December of 2013. Prior to that he served as a consultant and acting Chief Financial Officer for us from June 2012 to December 2013. From 2010 to 2012, Mr. Shah served as Director, Health Care Investment Banking for Citigroup Inc., where he was responsible for managing client relationships and executing strategic and financing related transactions for clients focused in life sciences. From 2004 to 2010 Mr. Shah was employed with Credit-Suisse, last serving in the capacity as Vice President, Health Care Investment Banking Group. Mr. Shah currently serves on the Board of Tvardi Therapeutics. Mr. Shah received a M.B.A. from Carnegie Mellon University Tepper School of Business and M.S. and B.S. degrees in Biomedical Engineering from Northwestern University.

What is Sujal Shah's net worth?: The estimated net worth of Sujal Shah is at least $5.56 million as of December 11th, 2023. Mr. Shah owns 171,301 shares of CymaBay Therapeutics stock worth more than $5,563,856 as of April 27th. This net worth evaluation does not reflect any other assets that Mr. Shah may own. Additionally, Mr. Shah receives an annual salary of $1,040,000.00 as CEO at CymaBay Therapeutics. Learn More about Sujal Shah's net worth.
How old is Sujal Shah?: Mr. Shah is currently 51 years old. There are 7 older executives and no younger executives at CymaBay Therapeutics. Learn More on Sujal Shah's age.
What is Sujal Shah's salary?: As the CEO of CymaBay Therapeutics, Inc., Mr. Shah earns $1,040,000.00 per year. Learn More on Sujal Shah's salary.
How do I contact Sujal Shah?: The corporate mailing address for Mr. Shah and other CymaBay Therapeutics executives is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. CymaBay Therapeutics can also be reached via phone at (510) 293-8800 and via email at [email protected]. Learn More on Sujal Shah's contact information.
Has Sujal Shah been buying or selling shares of CymaBay Therapeutics?: Sujal Shah has not been actively trading shares of CymaBay Therapeutics within the last three months. Most recently, Sujal Shah sold 64,865 shares of the business's stock in a transaction on Monday, December 11th. The shares were sold at an average price of $20.00, for a transaction totalling $1,297,300.00. Following the completion of the sale, the chief executive officer now directly owns 171,301 shares of the company's stock, valued at $3,426,020. Learn More on Sujal Shah's trading history.
Who are CymaBay Therapeutics' active insiders?: CymaBay Therapeutics' insider roster includes Janet Dorling (Director), Dennis Kim (Insider), Charles McWherter (Insider), Daniel Menold (VP), Paul Quinlan (General Counsel), Sujal Shah (CEO), and Kurt von Emster (Director). Learn More on CymaBay Therapeutics' active insiders.
Are insiders buying or selling shares of CymaBay Therapeutics?: In the last year, insiders at the biopharmaceutical company sold shares 27 times. They sold a total of 480,648 shares worth more than $7,806,823.97. The most recent insider tranaction occured on February, 12th when Director Janet Dorling sold 6,000 shares worth more than $191,820.00. Insiders at CymaBay Therapeutics own 7.0% of the company. Learn More about insider trades at CymaBay Therapeutics.
Information on this page was last updated on 2/12/2024.

Sujal Shah Insider Trading History at CymaBay Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/11/2023	Sell	64,865	$20.00	$1,297,300.00	171,301
10/9/2023	Sell	64,861	$14.20	$921,026.20	171,301
6/6/2022	Buy	51,301	$1.95	$100,036.95	171,301
10/10/2019	Buy	5,000	$4.30	$21,500.00	120,000
9/23/2019	Buy	5,000	$5.53	$27,650.00	111,900
9/20/2019	Buy	1,900	$5.50	$10,450.00	111,900
12/21/2018	Buy	10,000	$6.54	$65,400.00	110,000
10/15/2018	Buy	5,000	$9.90	$49,500.00	100,000
7/27/2018	Buy	5,000	$10.90	$54,500.00	95,000
5/11/2018	Buy	5,000	$10.65	$53,250.00	90,000
7/20/2017	Buy	10,000	$7.34	$73,400.00	75,891
4/5/2016	Buy	55,000	$1.39	$76,450.00	42,000
4/4/2016	Buy	22,000	$1.39	$30,580.00	42,000
5/18/2015	Buy	10,000	$3.40	$34,000.00

Sujal Shah Buying and Selling Activity at CymaBay Therapeutics

CymaBay Therapeutics Company Overview

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

Today's Range

Now: $32.48

$32.48

50 Day Range

MA: $32.40

$32.17

$32.48

2 Week Range

Now: $32.48

$7.26

$32.50

Volume

73 shs

Average Volume

4,113,430 shs

Market Capitalization

$3.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

Better than Bitcoin? The Biotech Stock with 46,751% Potential

From Behind the Markets | Ad

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>

Sujal Shah Biography and Net Worth

What is Sujal Shah's net worth?

How old is Sujal Shah?

What is Sujal Shah's salary?

How do I contact Sujal Shah?

Has Sujal Shah been buying or selling shares of CymaBay Therapeutics?

Who are CymaBay Therapeutics' active insiders?

Are insiders buying or selling shares of CymaBay Therapeutics?